drugset / Trial / NCT02690727

To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers

NCT02690727

Phase 1 Completed 18 enrolled Rhizen Pharmaceuticals SA
RandomizedCrossoverOpen-labelTreatment

Summary

This is a single centre, open label, randomized, two-treatment, two-period, two-sequence, single dose crossover food effect study in 18 subjects. The subjects will receive the study medication under either fed or fast during each treatment period.

Timeline

Start
2016-02
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenalisib Small molecule Oral

Indications

No indication recorded.